Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Abstract The global supply of COVID-19 vaccines remains limited. Immune markers were not correlated with asymptomatic infections at the 5% significance level.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines.
• 2 Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2.
• 3 Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: